Partner Robert (Bob) Haney, Jr. was recently featured in IAM discussing the growing convergence of biotech innovation and artificial intelligence. Fresh off J.P. Morgan Healthcare Week 2026, Haney spoke with IAM about how AI‑driven drug discovery is reshaping trade secret protection, the rise of employee‑mobility disputes in highly innovative industries, and the steps companies must prioritize as cross‑border scientific collaboration expands.
In the interview, Haney highlighted the increasing role of AI, big data, and computer‑generated research in life sciences, noting that the blending of biotech and software technologies is creating new categories of sensitive, high‑value information that require robust trade secret safeguards. He also discussed common pitfalls in employee departures, the importance of rigorous data‑return protocols, and recent developments in trade secret litigation—including the Ninth Circuit's decision in Quintara Biosciences v. Ruifeng Biztech.